- Home
- ANIX vs AGEN Comparison
ANIX vs AGEN Comparison
Compare ANIX & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- AGEN
- Stock Information
- Founded
- ANIX 1982
- AGEN 1994
- Country
- ANIX United States
- AGEN United States
- Employees
- ANIX 5
- AGEN N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANIX Health Care
- AGEN Health Care
- Exchange
- ANIX Nasdaq
- AGEN Nasdaq
- Market Cap
- ANIX 135.3M
- AGEN 126.8M
- IPO Year
- ANIX 1987
- AGEN 2000
- Fundamental
- Price
- ANIX $4.14
- AGEN $4.36
- Analyst Decision
- ANIX Strong Buy
- AGEN Buy
- Analyst Count
- ANIX 3
- AGEN 2
- Target Price
- ANIX $9.00
- AGEN $14.50
- AVG Volume (30 Days)
- ANIX 155.7K
- AGEN 479.6K
- Earning Date
- ANIX 09-10-2025
- AGEN 11-10-2025
- Dividend Yield
- ANIX N/A
- AGEN N/A
- EPS Growth
- ANIX N/A
- AGEN N/A
- EPS
- ANIX N/A
- AGEN N/A
- Revenue
- ANIX N/A
- AGEN $106,829,000.00
- Revenue This Year
- ANIX N/A
- AGEN $60.49
- Revenue Next Year
- ANIX N/A
- AGEN N/A
- P/E Ratio
- ANIX N/A
- AGEN N/A
- Revenue Growth
- ANIX N/A
- AGEN N/A
- 52 Week Low
- ANIX $2.07
- AGEN $1.38
- 52 Week High
- ANIX $4.98
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- ANIX 52.15
- AGEN 55.59
- Support Level
- ANIX $4.05
- AGEN $4.17
- Resistance Level
- ANIX $4.60
- AGEN $4.67
- Average True Range (ATR)
- ANIX 0.24
- AGEN 0.27
- MACD
- ANIX -0.02
- AGEN 0.07
- Stochastic Oscillator
- ANIX 48.05
- AGEN 65.09
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).